Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks
Open Access
- 27 November 2018
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 320 (20), 2108-2121
- https://doi.org/10.1001/jama.2018.16773
Abstract
Quiz Ref ID Hereditary angioedema with C1 inhibitor deficiency is a rare autosomal dominant disorder due to C1 inhibitor deficiency (type I) or dysfunction (type II) that leads to dysregulated plasma kallikrein activity, excess bradykinin production, and unpredictable potentially life-threatening recurrent angioedema attacks.1,2 Patients with hereditary angioedema are often limited in their ability to perform daily activities at work, school, or home; experience symptoms of anxiety and depression; face a risk of asphyxiation due to laryngeal attacks; and report poor health-related quality of life.3-5Keywords
This publication has 22 references indexed in Scilit:
- A phase 1 study investigating DX-2930 in healthy subjectsAnnals of Allergy, Asthma & Immunology, 2014
- Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking AntibodyOnline Journal of Public Health Informatics, 2014
- Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patientsClinical and Experimental Immunology, 2014
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Escalating Doses of C1 Esterase Inhibitor (CINRYZE) for Prophylaxis in Patients With Hereditary AngioedemaThe Journal of Allergy and Clinical Immunology: In Practice, 2013
- HAE Update: Epidemiology and burden of diseaseAllergy and Asthma Proceedings, 2013
- Development and construct validation of the angioedema quality of life questionnaireAllergy, 2012
- Congenital prekallikrein deficiencyExpert Review of Hematology, 2010
- Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary AngioedemaThe New England Journal of Medicine, 2010
- Hereditary AngioedemaThe New England Journal of Medicine, 2008